Amgen (AMGN) Change in Accured Expenses (2009 - 2026)

Amgen has reported Change in Accured Expenses for 18 years, with the latest figure at -$75.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 3.85% year-over-year to -$75.0 million; the trailing twelve-month figure through Mar 2026 stood at -$153.0 million (down 318.57% YoY), and the FY2025 full-year result was -$156.0 million, down 269.57% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$75.0 million, down from $94.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2023, with the low at -$501.0 million in Q3 2023.
• Average Change in Accured Expenses over 5 years is $53.6 million, with a median of -$75.0 million recorded in 2026.
• Peak annual rise in Change in Accured Expenses reached 401.37% in 2023, while the deepest fall reached 219.57% in 2023.
• Tracing AMGN's Change in Accured Expenses over 5 years: stood at -$366.0 million in 2022, then surged by 401.37% to $1.1 billion in 2023, then tumbled by 34.0% to $728.0 million in 2024, then plunged by 87.09% to $94.0 million in 2025, then slumped by 179.79% to -$75.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$75.0 million (Q1 2026), $94.0 million (Q4 2025), and -$180.0 million (Q3 2025), per Business Quant data.

Peer Comparison